Anindita Banerjee
Pfizer (United States)(US)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Hair Growth and Disorders, melanin and skin pigmentation, Chronic Lymphocytic Leukemia Research, Autoimmune Bullous Skin Diseases
Most-Cited Works
- → A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results(2021)185 cited
- → Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)(2017)175 cited
- → Oxidative DNA damage preventive activity and antioxidant potential of plants used in Unani system of medicine(2010)170 cited
- → Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial(2022)134 cited
- → Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers(2021)92 cited
- → Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study(2023)83 cited
- → Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial(2021)42 cited
- → Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia(2019)36 cited
- → Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study(2020)32 cited
- → Protective efficacy of Tinospora sinensis against streptozotocin induced pancreatic islet cell injuries of diabetic rats and its correlation to its phytochemical profiles(2019)29 cited